Blueprint Medicines Corporation

• NCT06327685

  Collaborator, Phase 1, Recruiting, 34 people, 25 Mar 2024

• NCT05252416

  Phase 1, Terminated, 50 people, 23 Feb 2022

• NCT05241873

  Phase 1, Terminated, 103 people, 16 Feb 2022

• NCT05153408

  Phase 1, Terminated, 20 people, 10 Dec 2021

• Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer

  Consulting or advice, Founder, Board or leadership role, 4 Mar 2026

• Beneficial Effects of Fisetin, a Senotherapeutic Compound, in Women's Reproductive Health and Diseases: Evidence from In Vitro to Clinical Studies

  Consulting or advice, 25 Jan 2026

• Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

  Consulting or advice, Fees or honoraria, 12 Jan 2026

• Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness

  Consulting or advice, Founder, Board or leadership role, 25 Nov 2025

• Oncogenic and tumor-suppressive forces converge on a progenitor-orchestrated niche to shape early tumorigenesis

  Consulting or advice, Shares or equity, 12 Jun 2025

Sources: pubmed.ncbi.nlm.nih.gov